for mobile/tablet users, please navigate using the menu located below.
  We are a dynamic and creative company who has evolved our business model to meet the changing needs of the life science industry.

Letter from CEO...

 
 
Investment Summary
Industry sector:   Therapeutics, biotech, start-up, med device/diagnostic, med-tech, small/specialty pharma
Size of investment:   30-70% cost of the development studies
Investment stage:   Preclinical, IND-enabling, tox, Phase I-III
Return on investment:   Equity, downstream royalties, milestone payments, etc.
Geography:   Primarily US, UK and rest of EU, Israel